---
document_datetime: 2023-09-21 17:42:06
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-dura-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-dura-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.9214469
conversion_datetime: 2025-12-26 16:56:05.060748
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Clopidogrel DURA

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                           | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                               |
|----------------------|---------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/00820          | Periodic Safety Update EU Single assessment - ACETYLSALICYLIC ACID, CLOPIDOGREL | 10/07/2014                                  | n/a                                            |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                     |
| R/0017               | Renewal of the marketing authorisation.                                         | 20/03/2014                                  | 22/05/2014                                     | SmPC, Annex II, Labelling and PL | The safety and efficacy of clopidogrel have been demonstrated by several large clinical studies. No literature review on the efficacy/effectiveness has been submitted by the MAH within this application. Since the clinical efficacy of clopidogrel in the approved indications is well established and evidence of clinical efficacy has been discussed at time of |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | To update sections 4.4 and 4.5 of the SmPC to add information on an interaction with the selective   | approval the CHMP finds acceptable performing a literature review of clopidogrel. The beneficial effect of Clopidogrel that of the originator product positive. longer authorised   |
|-----------|------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0019/G | This was an application for a group of variations.                                                   | 23/04/2014 SmPC and PL                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           | MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |               |                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|----------------------------------|
| IB/0016   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                         | 19/12/2013 | 22/01/2014    | SmPC                             |
| IB/0015/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product | 14/11/2013 | 22/01/2014 no | SmPC longer authorised           |
| IB/0014/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a Medicinal                                                                                                                                                                                                          | 16/09/2013 | 22/01/2014    | SmPC, Annex II, Labelling and PL |

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                          |                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| IB/0013/G | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                  | 21/05/2013 22/01/2014 longer |
| IB/0012/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation Medicinal product | 08/03/2013 n/a no            |
| IA/0011/G | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase                                                                                                                                                                                                                                                                    | 18/01/2013 n/a               |

<div style=\"page-break-after: always\"></div>

|         | compared to the currently approved batch size A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                      |            |            |                       | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010 | B.II.a.3.z - Changes in the composition (excipients) of the finished product - Other variation                                                                                                                                                                   | 18/01/2013 | 22/01/2014 | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0009 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                   | 08/08/2011 | n/a        | SmPC longer           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0008 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                    | 13/04/2011 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0007 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH Medicinal product | 11/03/2011 | n/a no     | SmPC, Annex II and PL | To update the Summary of Product Characteristics and Package Leaflet of the concerned product following assessment of the same change for the reference product Plavix further to the adoption by the CHMP of the following conclusions: Amendments should be introduced in the Summary of Product Characteristics (SPC) and Package Leaflet to update sections 4.2 \"Posology and method of administration'; 4.4 \"Special warnings and precautions for use\", 4.5 \"Interaction with other medicinal products and other forms of interaction\" and 5.2 \"Pharmacokinetic properties\" of clopidogrel/acetylsalicylic acid (ASA) SPC to include new information on the variability of response to clopidogrel due to either genetic variations of the CYP2C19 enzyme or concomitant use of drugs that inhibit the CYP2C19 enzyme such as proton pump inhibitor (PPI). In addition, section 4.8 has been amended with minor details on the |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                      |            |            |                        | CURE study. Additional changes have been added to the SPC and Package Leaflet in order to bring it in line with the revised QRD template (version 7.3). In addition, the deletion of DDPS number 1.3 and dated 24 April 2008 was introduced in Annex IIB as requested by the EMA with the procedural announcement in October and November 2010. authorised   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0006   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                       | 11/08/2010 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                              |
| IB/0004/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation product | 08/06/2010 | n/a no     | longer                 |                                                                                                                                                                                                                                                                                                                                                              |
| IA/0005   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer Medicinal                                                                             | 03/06/2010 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                              |
| IB/0003   | IB_18_Replacement of an excipient with a comparable excipient                                                                                                                                                                                                                                        | 25/01/2010 | n/a        | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                              |
| II/0001   | addition of alternative manufcture for an intermediate                                                                                                                                                                                                                                               | 17/12/2009 | 06/01/2010 |                        |                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| and change in manufacturer process of intermediate Change(s) to the manufacturing process for the active substance   |
|----------------------------------------------------------------------------------------------------------------------|

Medicinal product no longer authorised